62 completed, 16 unknown, 11 recruiting, 6 terminated. 28 Not applicable, 24 Phase 2, 12 Phase 1, 8 Phase 4, 4 Phase 3.
Follow Nonalcoholic Fatty Liver Disease: new trials by email Literature Review of Nonalcoholic Fatty Liver Disease trials Research Report on Nonalcoholic Fatty Liver Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease 5-methyltetrahydrofolate (5-MTHF), placebo group - Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD) | Not applicable | Not yet recruiting | Tabriz University of Medical Sciences | 44 | 2026-09-30 | 2026-07-31 |
| iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss Endoscopic Radial Compression Gastroplasty, Optimized Lifestyle Intervention (OLI) - Overweight and/or Obesity, Metabolic Syndrome | Not applicable | Recruiting | Liu Yan | 216 | 2026-03-01 | 2026-03-13 |
| Brown Adipose Tissue Activity and NAFLD Progression Nonalcoholic Fatty Liver Disease | Completed | Renmin Hospital of Wuhan University | 96 | 2026-01-05 | 2026-09-17 | |
| Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis Embospheres Microspheres - Obesity, Weight Loss | Not applicable | Not yet recruiting | Keith Pereira, MD: | 8 | 2025-12-01 | 2025-07-28 |
| The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast - Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD) | Not applicable | Recruiting | University of Nottingham | 45 | 2025-06-10 | 2026-07-29 |
| Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases No intervention - Metabolic Syndrome (MetS), Obesity & Overweight | Recruiting | Chang Gung Memorial Hospital | 6266 | 2025-06-09 | 2025-11-25 | |
| To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease | Recruiting | Tongji Hospital | 500 | 2025-04-01 | 2025-09-02 | |
| Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD TLC-2716 Dose 1, TLC-2716 Dose 2, Placebo - Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease | Phase 2 | Unknown | OrsoBio, Inc | 30 | 2024-08-12 | 2025-04-03 |
| Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) Efinopegdutide - Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | Merck Sharp & Dohme LLC | 124 | 2024-07-29 | 2026-06-01 |
| Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD Henagliflozein and Metformin, Linagliptin and Metformin - Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease | Phase 4 | Recruiting | Zhujiang Hospital | 100 | 2024-06-01 | 2024-06-10 |
| Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines Exercise, Motivational Interviewing - NAFLD, Nonalcoholic Fatty Liver Disease | Not applicable | Unknown | Yeditepe University | 144 | 2024-01-05 | 2024-02-26 |
| Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） Peg-Interferon α - Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 1500 | 2024-01-01 | 2024-04-16 |
| Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease Nonalcoholic Fatty Liver Disease | Unknown | Massachusetts General Hospital | 60 | 2023-12-01 | 2023-12-12 | |
| A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria BMN 255, Placebo - Hyperoxaluria, Nonalcoholic Fatty Liver Disease | Phase 1 | Withdrawn | BioMarin Pharmaceutical | 2023-09-26 | 2024-06-11 | |
| A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Efinopegdutide, Semaglutide, Placebo - Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2023-06-23 | 2026-01-12 |
| Phase 2b Study of GSK4532990 in Adults With NASH GSK4532990, Placebo - Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | Phase 2 | Active not recruiting | GlaxoSmithKline | 284 | 2023-01-02 | 2026-09-18 |
| Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease - Nonalcoholic Fatty Liver Disease | Not applicable | Unknown | Hangzhou Tangji Medical Technology Co., Ltd. | 10 | 2022-12-15 | 2024-06-26 |
| Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US Saroglitazar Magnesium 4 mg, Placebo - Nonalcoholic Fatty Liver Disease | Phase 2 | Terminated | Zydus Therapeutics Inc. | 4 | 2022-12-08 | 2025-09-02 |
| Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Endoscopic Sleeve Gastroplasty - Nonalcoholic Fatty Liver Disease | Active not recruiting | West Virginia University | 30 | 2022-08-24 | 2026-04-24 | |
| Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease AZD7503 Intervention - Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 1 | Completed | AstraZeneca | 19 | 2022-08-12 | 2025-07-20 |
Showing 20 of 102. Sign in to see all of them.
Non-alcoholic Fatty Liver Disease (102) · Obesity (14) · Fatty Liver (12) · Diabetes Mellitus, Type 2 (10) · Metabolic Syndrome (7) · Insulin Resistance (6) · Inflammation (5) · Liver Cirrhosis (5) · Dyslipidemias (3) · Fibrosis (3) · Hepatitis B, Chronic (3) · Liver Diseases (3) · Weight Loss (3) · Cardiovascular Diseases (2) · Intermittent Fasting (2)
Digestive System Diseases (101) · Liver Diseases (99) · Fatty Liver (90) · Nutritional and Metabolic Diseases (37) · Pathological Conditions, Signs and Symptoms (30) · Metabolic Diseases (28) · Glucose Metabolism Disorders (23) · Nutrition Disorders (17) · Overnutrition (16) · Pathologic Processes (16) · Signs and Symptoms (16) · Body Weight (15) · Overweight (14) · Endocrine System Diseases (12) · Hyperinsulinism (12)
Exercise (5) · Metformin (4) · Diet (3) · Exenatide (3) · Docosahexaenoic Acids (2) · Pegbelfermin (2) · Pioglitazone (2) · Vitamin E (2) · ervogastat (2) · semaglutide (2) · 5-methyltetrahydrofolate (1) · Acetylcysteine (1) · Anthocyanins (1) · BID protein, human (1) · Berberine (1)
Ningbo No. 1 Hospital (5) · Bristol-Myers Squibb (3) · Chinese University of Hong Kong (3) · Maastricht University Medical Center (3) · Merck Sharp & Dohme LLC (3) · Pfizer (3) · Bambino Gesù Hospital and Research Institute (2) · Nanfang Hospital, Southern Medical University (2) · Shaoguan University (2) · University of California, San Diego (2) · University of Florida (2) · Virginia Commonwealth University (2) · Ahlia University (1) · Assy Nimer (1) · AstraZeneca (1)
United States (40) · China (29) · Canada (8) · Israel (8) · Italy (6) · South Korea (6) · Turkey (Türkiye) (6) · Taiwan (5) · France (4) · Mexico (4) · Poland (4) · Puerto Rico (4) · Spain (4) · United Kingdom (4) · Australia (3)
Huijie Zhang, MD,PhD (2) · Kenneth Cusi, M.D. (2) · Valerio Nobili, MD (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Alison Ehrlich, MD, MHS (1) · Amira B. Kassem, Lecturer (1) · Amreen Dinani (1) · An Tang, MD (1) · Arnon Aharon, MD (1) · Arun J. Sanyal, M.D. (1) · Arun Sanyal, MD (1) · Assim Alfadda, MD (1)
PMID 33210751, PMID 36930148, PMID 17581899, PMID 18086506, PMID 18796671, PMID 20460906, PMID 21131943, PMID 21233083, PMID 21299450, PMID 21411114, PMID 22367009, PMID 22488764, PMID 22676459, PMID 23034128, PMID 23140654, PMID 23220074, PMID 23396737, PMID 23401313, PMID 23537027, PMID 23623998, PMID 23707905, PMID 24074360, PMID 24377455, PMID 24449368, PMID 24462005, PMID 24631112, PMID 24899158, PMID 25040896, PMID 25285192, PMID 25349724, PMID 25581263, PMID 25813773, PMID 25948673, PMID 25997043, PMID 26198758, PMID 26252777, PMID 26493259, PMID 26599819, PMID 26629307, PMID 26829441, PMID 26914659, PMID 27322798, PMID 27567998, PMID 27629750, PMID 29223443, PMID 29885082, PMID 29942422, PMID 30667502, PMID 31013363, PMID 31559605
U01DK061737 (2), 2017 (1), 2018 (1), 2019 (1), 2023 (1), R01DK113701 (1), U01DK061713 (1), U01DK061718 (1), U01DK061728 (1), U01DK061731 (1), U01DK061732 (1), U01DK061734 (1), U01DK061738 (1), U24DK061730 (1), UL1TR000058 (1)